Gentium Upgraded to Strong Buy - Analyst Blog
03 Janeiro 2014 - 3:50PM
Zacks
On Jan 2, 2014, Zacks Investment Research upgraded
Gentium (GENT) to a Zacks Rank #1 (Strong
Buy).
Why the Upgrade?
Shares of Gentium, an Italy-based biopharma company, have been on
an uptrend, gaining 2.5%, since the announcement of its takeover by
Jazz Pharmaceuticals (JAZZ). Jazz Pharma will
acquire Gentium for $57.00 per share in cash or $1 billion.
The offer price of $57.00 per share represents a 2.4% premium to
Gentium’s closing price of $55.65 per share on Dec 19, 2013. The
transaction is expected to close in the first quarter of 2014.
Gentium’s lead product, Defitelio is approved in the EU (Oct 2013)
for the treatment of severe hepatic veno-occlusive disease (VOD) in
patients undergoing hematopoietic stem cell transplantation. The
company expects to start obtaining pricing approvals in EU
countries in the first quarter of 2014, extending up to 2015.
A regulatory application for Defitelio is expected to be submitted
in the first half of 2014 in the U.S. The FDA has granted Fast
Track Designation to Defitelio for the VOD indication.
Defitelio enjoys Orphan Drug status in both the U.S. and EU for the
treatment and prevention of VOD. In the EU, Defitelio was granted
an Orphan Drug designation for the prevention of graft versus host
disease as well. Defitelio is also being evaluated for prevention
of VOD (phase III).
Other Stocks to Consider
Other players in the pharma industry, which look attractive at
current levels, include Jazz Pharma, Lannett Company,
Inc. (LCI) and Forest Laboratories Inc.
(FRX). All these stocks carry the same Zacks Rank as Gentium.
FOREST LABS A (FRX): Free Stock Analysis Report
GENTIUM SPA-ADR (GENT): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
London Clubs (AMEX:LCI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
London Clubs (AMEX:LCI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Lannett CO da American Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de London Clubs